Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)

समान संसाधन

• Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
  द्वारा: Corcoran, Ryan B., और अन्य
  प्रकाशित: (2015)
• Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF(V600)-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
  द्वारा: Johnson, Douglas B., और अन्य
  प्रकाशित: (2014)
• Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
  द्वारा: Minor, David R., और अन्य
  प्रकाशित: (2015)
• Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma
  द्वारा: Laino, Antonia, और अन्य
  प्रकाशित: (2018)
• Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation
  द्वारा: Teshima, Yasutomo, और अन्य
  प्रकाशित: (2020)